MarketBeat
09 Aug 2026, 03:04 UTC · 2h ago
Arcus Biosciences Q2 Earnings Call Highlights
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
MarketBeat
09 Aug 2026, 03:04 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Arcus estimates the total peak sales potential for its lead drug casdatifan at between $5 billion and $10 billion. — Establishing a multi-billion dollar peak sales target for a lead asset provides a concrete valuation anchor for investors.
+0.80Arcus will present clinical data from over 200 patients across the casdatifan program at an investor event in October. — Upcoming data readouts for a primary asset are high-volatility catalysts that can significantly move the stock price.
+0.60Analysis of 120 late-line patients suggests casdatifan does not share the inverse relationship between prior TKI exposure and efficacy seen in belzutifan. — If proven, this provides a competitive advantage over a known competitor's drug, expanding the treatable patient population.
+0.50Continue reading
6 related stories
Top 3 movers · tap to explore
The Phase III PEAK-1 trial for previously treated ccRCC is on track to finish enrollment by the end of 2026. — Confirms the timeline for the first registrational study, though the date is far enough out to limit immediate impact.
+0.30The company expects to end 2026 with approximately $600 million in cash and investments. — Provides clarity on the financial runway and reduces immediate concerns regarding capital raises for the pipeline.
+0.20Which stocks this story touches
The company is expanding its lead cancer program with high peak sales potential and providing positive pipeline updates.
Entering a collaboration to study casdatifan-containing regimens in a platform trial.
Partnering with Arcus to study a combination therapy for later-line renal cell carcinoma.
Entering a collaboration to study casdatifan with bispecific antibodies.
[mutual] Arcus and Bristol Myers Squibb have a collaboration to study casdatifan with anti-PD-1/VEGF bispecific antibodies.
[mutual] Arcus and Summit Therapeutics are collaborating to study casdatifan combined with a specific cohort in the ARC-20 study.
[mutual] Arcus is working with AVEO Oncology to study the combination of casdatifan and tivozanib.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
MarketBeat
1h ago
